aripiprazole has been researched along with Substance Withdrawal Syndrome in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, PP; Sanchez, R; Such, P | 1 |
| Correll, CU; Iwata, N; Kishi, T; Matsuda, Y | 1 |
| Philip, NS | 1 |
| Francis, A; Hameed, A; Mahgoub, Y | 1 |
| Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, P; Salzman, PM; Sanchez, R; Such, P | 1 |
| Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G | 1 |
| Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R | 1 |
| Bao, YP; Beveridge, TJ; Di, XL; Li, SX; Liu, Y; Lu, L; Sun, HQ; Yang, FD | 2 |
| Cho, DY; Lindenmayer, JP | 1 |
| Barnett, RJ; Cauble, S; McLaren, JL | 1 |
| Kurokawa, K; Mizuno, K; Ohkuma, S; Shibasaki, M | 1 |
| Campistol, J; Darling, A; Perez-Duenas, B; Poo, P | 1 |
| Bennett, N; Hirsch, J; Kafantaris, V; Saito, E | 1 |
| Baciu, D; Walther, S | 1 |
| Koch, M; Schwabe, K | 1 |
| Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA | 1 |
2 review(s) available for aripiprazole and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dopamine; Dopamine Uptake Inhibitors; Humans; Methamphetamine; Olanzapine; Outcome Assessment, Health Care; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Substance Withdrawal Syndrome; Synaptic Transmission; Treatment Outcome | 2013 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Child, Preschool; Dopamine; Dopamine Antagonists; Down Syndrome; Dyskinesia, Drug-Induced; Dystonic Disorders; Electroencephalography; Epilepsy; Female; Fragile X Syndrome; Humans; Intellectual Disability; Isoxazoles; Male; Methotrimeprazine; Ocular Motility Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Risperidone; Substance Withdrawal Syndrome; Translocation, Genetic; Valproic Acid | 2013 |
6 trial(s) available for aripiprazole and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Conduct Disorder; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Psychomotor Agitation; Substance Withdrawal Syndrome; Weight Gain; Young Adult | 2018 |
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Topics: Administration, Oral; Adult; Affect; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome | 2017 |
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.
Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Piperazines; Quinolones; Secondary Prevention; Substance Withdrawal Syndrome | 2009 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult | 2009 |
Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention; Blood Pressure; China; Cognition; Cross-Over Studies; Cues; Data Interpretation, Statistical; Heart Rate; Humans; Male; Memory, Short-Term; Piperazines; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2009 |
Long-term treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Double-Blind Method; Female; Humans; Male; Pilot Projects; Piperazines; Postprandial Period; Quinolones; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Tobacco Use Disorder; Young Adult | 2010 |
9 other study(ies) available for aripiprazole and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
An aripiprazole discontinuation syndrome.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2013 |
Covert Dyskinesia With Aripiprazole: A Case Report.
Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Substance Withdrawal Syndrome | 2016 |
Aripiprazole-induced agitation after clozapine discontinuation: a case report.
Topics: Akathisia, Drug-Induced; Alcoholism; Antipsychotic Agents; Aripiprazole; Clozapine; Cocaine-Related Disorders; Comorbidity; Delayed-Action Preparations; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Middle Aged; Molindone; Piperazines; Quinolones; Schizophrenia, Paranoid; Substance Withdrawal Syndrome | 2009 |
Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Drug Administration Schedule; Dystonia; Humans; Male; Methylphenidate; Piperazines; Quinolones; Substance Withdrawal Syndrome | 2010 |
Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference.
Topics: Alcoholism; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Dopamine; Ethanol; Male; Mice; Piperazines; Pyridines; Quinolones; Substance Withdrawal Syndrome; Time Factors | 2012 |
Treatment of withdrawal dyskinesia.
Topics: Adolescent; Amino Acids, Branched-Chain; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Examination; Piperazines; Quinolones; Substance Withdrawal Syndrome; Treatment Outcome | 2005 |
[No rebound psychosis in a case of switching from clozapine to quetiapine].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brief Psychiatric Rating Scale; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Agents; Dose-Response Relationship, Drug; Male; Motivation; Piperazines; Quinolones; Rats; Rats, Wistar; Reinforcement Schedule; Reward; Substance Withdrawal Syndrome | 2007 |
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Readmission; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Sensitivity and Specificity; Substance Withdrawal Syndrome; Survival Rate; Thiazoles | 2008 |